Recent Finacing
Recent Raise
HepaRegeniX is a Tuebingen clinical-stage biopharma developing oral small-molecule MKK4 inhibitors, including HRX-215 (Phase Ib/IIa), to stimulate hepatocyte regeneration for post‑hepatectomy failure and severe liver disease.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
